+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Adhera Therapeutics
  • Assembly Biosciences Inc
  • Cocrystal Pharma Inc
  • Silence Therapeutics Plc
  • MORE
Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corporation, focuses on the discovery, development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection (HBV). Its pipeline includes capsid assembly inhibitors AB-729, AB-836 and PD_L1; AB-729 a second generation RNAi therapeutics which is under development using N-acetylgalactosamine (GalNAc) delivery technology and PD-L1 a HBV RNA destabilizer. The company develops product candidates based on its lipid nanoparticle (LNP) delivery technology. Arbutus Biopharma seeks to partnership and collaboration with Genevant Sciences Inc, Alnylam Pharmaceuticals Inc, Acrotech Biopharma LLC and Gritstone Oncology. It operates in the US and Canada. Arbutus Biopharma is headquartered in Burnaby, British Columbia, Canada.

Arbutus Biopharma Corp Key Recent Developments

May 11, 2020: Arbutus reports first quarter 2020 financial results, provides pipeline update and announces new research initiative to identify novel antiviral therapies for the treatment of coronavirus infections
Mar 05, 2020: Arbutus reports fourth quarter and year end 2019 financial results, confirms 2020 corporate objectives and provides pipeline update
Nov 06, 2019: Arbutus reports third quarter 2019 financial results and provides corporate update
Aug 20, 2019: Arbutus Biopharma appoints Andrew Cheng, M.D., Ph.D., to its board of directors
Aug 05, 2019: Arbutus reports second quarter 2019 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adhera Therapeutics
  • Assembly Biosciences Inc
  • Cocrystal Pharma Inc
  • Silence Therapeutics Plc
  • MORE
Section 1 - About the Company
  • Arbutus Biopharma Corp - Key Facts
  • Arbutus Biopharma Corp - Key Employees
  • Arbutus Biopharma Corp - Key Employee Biographies
  • Arbutus Biopharma Corp - Major Products and Services
  • Arbutus Biopharma Corp - History
  • Arbutus Biopharma Corp - Company Statement
  • Arbutus Biopharma Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 – Company Analysis
  • Company Overview
  • Arbutus Biopharma Corp - Business Description
  • Arbutus Biopharma Corp - Corporate Strategy
  • Arbutus Biopharma Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Arbutus Biopharma Corp - Strengths
  • Arbutus Biopharma Corp - Weaknesses
  • Arbutus Biopharma Corp - Opportunities
  • Arbutus Biopharma Corp - Threats
  • Arbutus Biopharma Corp - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Arbutus Biopharma Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • May 11, 2020: Arbutus reports first quarter 2020 financial results, provides pipeline update and announces new research initiative to identify novel antiviral therapies for the treatment of coronavirus infections
  • Mar 05, 2020: Arbutus reports fourth quarter and year end 2019 financial results, confirms 2020 corporate objectives and provides pipeline update
  • Nov 06, 2019: Arbutus reports third quarter 2019 financial results and provides corporate update
  • Aug 20, 2019: Arbutus Biopharma appoints Andrew Cheng, M.D., Ph.D., to its board of directors
  • Aug 05, 2019: Arbutus reports second quarter 2019 financial results and provides corporate update
  • Jul 23, 2019: Veritas reaches a mutual settlement with Arbutus Biopharma
  • Jun 17, 2019: Arbutus appoints William Collier as next president & CEO and announces retirement of current President & CEO, Mark J. Murray Ph.D.
  • May 06, 2019: Arbutus reports first quarter 2019 financial results and provides corporate update
  • Mar 07, 2019: Arbutus Reports fourth quarter and year-end 2018 financial results and describes recent clinical accomplishments and key 2019 objectives
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • Arbutus Biopharma Corp, Key Facts
  • Arbutus Biopharma Corp, Key Employees
  • Arbutus Biopharma Corp, Key Employee Biographies
  • Arbutus Biopharma Corp, Major Products and Services
  • Arbutus Biopharma Corp, History
  • Arbutus Biopharma Corp, Joint Venture
  • Arbutus Biopharma Corp, Key Competitors
  • Arbutus Biopharma Corp, Ratios based on current share price
  • Arbutus Biopharma Corp, Annual Ratios
  • Arbutus Biopharma Corp, Annual Ratios (Cont...1)
  • Arbutus Biopharma Corp, Interim Ratios
  • Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Arbutus Biopharma Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Arbutus Biopharma Corp, Performance Chart (2015 - 2019)
  • Arbutus Biopharma Corp, Ratio Charts
  • Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Dicerna Pharmaceuticals Inc
  • Assembly Biosciences Inc
  • Adhera Therapeutics
  • Silence Therapeutics Plc
  • SELLAS Life Sciences Group Inc
  • Roche Innovation Center Copenhagen A/S
  • Cocrystal Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll